psychiatric conditions | GenomeWeb

psychiatric conditions

The deal will grant Myriad entry into the neuroscience space, and will allow it to use Assurex's existing sales force to market its own mental health tests. 

The firm plans to launch testing in the US this fall through Atlanta-based Alpha Genomix, and is looking for similar partners in Asia for a new Asia-specific panel.

Researchers identified Neanderthal alleles associated with human conditions using genotypic and phenotypic information in health records for more than 28,000 individuals. 

The RNA products developer is buying California-based Narus in order to expand into the RNA-based diagnostics market.

Following from genetic studies of compulsive behavior in dogs, researchers have starting collecting behavioral information for dogs in the Darwin's Dogs project.

Researchers tracked one individual's brain imaging patterns, physical features, blood metabolomics, gene expression, and more.

The mental health-focused testing firm plans to use the money to conduct additional studies for Genecept and develop a next-generation product.

The effort will compare the outcomes and healthcare costs of patients whose treatments were informed by genetic testing results against those managed without this information.

NEW YORK (GenomeWeb) – The Stanley Center at the Broad Institute has received a promise of $650 million from philanthropist Ted Stanley to fund genomic research of psychiatric disorders in order to eventually identify and develop molecularly targeted drugs.

Pages

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.